Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Moderna and Merck announced Thursday that their personalized mRNA cancer vaccine reduced the risk of death or recurrence by 42% compared to standard treatment in a late-stage melanoma trial.